Awardee OrganizationCOLUMBIA UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
CANCER POPULATION SCIENCE PROGRAM: PROJECT SUMMARY
The overarching goal of the Cancer Population Science (CPS) Program is to reduce the burden from cancer
on a population level. Given that goal, the CPS Program conducts observational, cohort, and interventional
studies that focus on primary prevention, early detection, health outcomes, and the delivery of cancer care to
diverse communities and populations affected, or potentially affected, by cancer. The CPS program is led by
Dawn Hershman, MD, MS and co-led by Mary Beth Terry, PhD and Regina Santella, PhD; each is a
nationally renowned leader in her discipline with a durable track record of mentorship. The CPS program
comprises 44 members, crossing three schools and representing 18 departments, with expertise across the
lifespan, and research a broad spectrum of cancer diagnoses. The CPS program has four interrelated Specific
Aims that cross the Cancer Care Continuum: (1) Etiology and Primary Prevention: Investigate environmental,
lifestyle and genetic factors that impact cancer risk across the lifespan in healthy populations to improve primary
prevention; (2) Risk Assessment and Early Detection: Integrate molecular- genetic- and imaging-based
biomarkers into clinical risk assessment and early detection; (3) Health Outcomes and Cancer Care Delivery:
Study patterns of cancer care to inform cost-effective cancer treatment and care delivery interventions and policy
initiatives aimed at patients, providers, and health systems; (4) Cancer Control: Discover strategies and translate
them to pathway and data-driven trials for patients living with cancer, with a specific focus on symptom
management, cancer survivorship and palliative care. In 2019, the CPS program had a total of $14M in cancer-
focused, peer-reviewed funding (direct costs), of which almost $4M (27%) was from NCI, $5.5M (38%) was from
other NIH sources, and $4.8M (34%) from other peer-reviewing agencies. During the project period, members
authored a total of 1,050 cancer relevant publications, of which 316 (30%) were intra-programmatic, 230 (22%)
were inter-programmatic, and 11% in high-impact journals with an impact factor of >10. In addition to numerous
epidemiologic and cohort studies, the CPS Program has strengths in leading both institutional and multicenter
interventional trials. During the project period the CPS program, had 947 interventional enrollments of which
85% were to investigator-initiated trials. CPS Program members also led and completed seven NCORP/NCTN
multicenter trials with an additional eight trials continuing to accrue at multiple sites. Under-represented minority
patients’ accrual to interventional trials is a particular strength of the CPS program and is 65%. The HICCC has
provided support, totaling close to $3M, and resources to foster the growth and development of the CPS Program
as a future strategic priority. Over the next project period we will continue to recruit new faculty based upon
strategic priorities, develop new initiatives in implementation and dissemination research, continue to lead
NCORP and other NCI initiatives and foster the development of trainees and junior faculty.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAdherenceAdvocateAffectAgreementAreaBiological MarkersCancer BurdenCancer CenterCancer Center Support GrantCancer ControlCancer EtiologyCancer SurvivorshipCatchment AreaChemopreventionClinical TrialsCohort StudiesCollaborationsCommunitiesCommunity Health EducationContinuity of Patient CareCreativenessDataDecision AidDevelopmentDirect CostsDisciplineDisparityDoctor of PhilosophyEarly DiagnosisEducational ActivitiesEnrollmentEpidemiologistEtiologyFacultyFosteringFundingFutureGeneticGoalsGrowth and Development functionHealthHealth systemInstitutionInterventionIntervention StudiesIntervention TrialJournalsLaboratoriesLeadLeadershipLife Cycle StagesLife StyleMalignant Breast NeoplasmMalignant NeoplasmsMedical OncologistMentorshipModelingMolecularMolecular EpidemiologyMolecular GeneticsMulticenter TrialsNewly DiagnosedObservational StudyOutcomePalliative CarePathway interactionsPatientsPatternPeer ReviewPilot ProjectsPoliciesPopulationPopulation SciencesPreventionPrimary PreventionProviderPublicationsResearchResearch PersonnelResearch PriorityResource SharingResourcesRiskRisk AssessmentSchoolsSecondary PreventionSiteSourceSupportive careTimeTranslatingUnderrepresented MinorityUnited States National Institutes of HealthWomananti-cancer researchcancer carecancer diagnosiscancer epidemiologycancer preventioncancer riskcancer therapycare deliverychemical carcinogenesisclinical riskcollaborative environmentcost effectivecost effective treatmentdensitydissemination researchenergy balanceepidemiology studyexperienceglobal healthimaging biomarkerimplementation researchimplementation strategyimprovedintervention deliveryinvestigator-initiated triallife spanmembermentoring communityminority patientorganizational structureoutreachprogramsrecruitscreeningsurvivorshipsymptom management
No Sub Projects information available for 5P30CA013696-49 5611
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30CA013696-49 5611
Patents
No Patents information available for 5P30CA013696-49 5611
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30CA013696-49 5611
Clinical Studies
No Clinical Studies information available for 5P30CA013696-49 5611
News and More
Related News Releases
No news release information available for 5P30CA013696-49 5611
History
No Historical information available for 5P30CA013696-49 5611
Similar Projects
No Similar Projects information available for 5P30CA013696-49 5611